Gilead Sciences, Yipinhong Pharmaceutical and Mass General Brigham Ventures helped the slow-release drug developer secure series C cash bringing its overall funding to almost $250m.
US-based slow-release drug developer Lyndra Therapeutics has completed a $60.5m series C round led by AIG Investments, an affiliate of insurance and financial services group American International Group.
Biopharmaceutical company Gilead Sciences, contract drug manufacturer Yipinhong Pharmaceutical and Mass General Brigham Ventures, the corporate venturing arm of healthcare provider Mass General Brigham, also contributed to the funding.
The round also featured philanthropic venture capital fund Catalytic Impact Foundation, which invests in partnership with ImpactAssets, in addition to Polaris Partners, Invus,…
